The Dual Role of TREM2 in 5xFAD Alzheimer's Disease Mouse Models :Implications for Targeting Strategies
DOI:
https://doi.org/10.64135/9ngefp65Keywords:
TREM2, 5xFAD model, Alzheimer's disease, microglia, targeted therapyAbstract
This review explores the dual role of TREM2 (Triggered Receptor Expressed on Myeloid cells 2) in the 5xFAD Alzheimer's disease (AD) mouse model and its potential implications for targeted therapeutic strategies. TREM2, a key regulator of microglia, exhibits complex dual effects of neuroprotection and neurotoxicity in AD pathogenesis. In recent years, with deepening insights into AD pathogenesis, TREM2's roles in Aβ clearance, metabolic homeostasis maintenance, and inflammatory regulation have garnered increasing attention. However, TREM2 may exhibit diametrically opposed functions across different disease stages and activation states, posing challenges for targeted therapies. This paper systematically elucidates TREM2's protective role in the 5xFAD model (e.g., promoting Aβ clearance, maintaining neuronal function) alongside its potential harmful effects (e.g., driving pathological inflammation), and analyzes the mechanisms underlying its dual roles (e.g., disease stage dependency, activation level dependency). Based on existing research, this paper further summarizes the challenges facing TREM2-targeted therapies and explores novel strategies for precisely regulating TREM2 function, providing theoretical foundations and directions for future AD treatments.
References
[1] Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth GE, Howell GR, Ransohoff RM, Lamb BT. TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models. J Exp Med. 2015 Mar 9;212(3):287-95. doi: 10.1084/jem.20142322. Epub 2015 Mar 2. PMID: 25732305; PMCID: PMC4354365.
[2] Rachmian N, Medina S, Cherqui U, Akiva H, Deitch D, Edilbi D, Croese T, Salame TM, Ramos JMP, Cahalon L, Krizhanovsky V, Schwartz M. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain. Nat Neurosci. 2024 Jun;27(6):1116-1124. doi: 10.1038/s41593-024-01620-8. Epub 2024 Apr 18. PMID: 38637622.
[3] Pádua MS, Guil-Guerrero JL, Lopes PA. Behavioral Hallmarks in the Alzheimer's Disease 5xFAD Mouse Model. Int J Mol Sci. 2024 Jun 20;25(12):6766. doi: 10.3390/ijms25126766. PMID: 38928472; PMCID: PMC11204382.
[4] Schreiner TG, Schreiner OD, Adam M, Popescu BO. The Roles of the Amyloid Beta Monomers in Physiological and Pathological Conditions. Biomedicines. 2023 May 10;11(5):1411. doi: 10.3390/biomedicines11051411. PMID: 37239082; PMCID: PMC10216198.
[5] Kalyaanamoorthy S, Opare SK, Xu X, Ganesan A, Rao PPN. Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology. Current Alzheimer Research. 2024; 21(1):24-49. doi: 10.2174/0115672050301407240408033046. PMID: 38623984.
[6] Zhou Y, Song WM, Andhey PS, Swain A, Levy T, Miller KR, Poliani PL, Cominelli M, Grover S, Gilfillan S, Cella M, Ulland TK, Zaitsev K, Miyashita A, Ikeuchi T, Sainouchi M, Kakita A, Bennett DA, Schneider JA, Nichols MR, Beausoleil SA, Ulrich JD, Holtzman DM, Artyomov MN, Colonna M. Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer's disease. Nat Med. 2020 Jan;26(1):131-142. doi: 10.1038/s41591-019-0695-9. Epub 2020 Jan 13. Erratum in: Nat Med. 2020 Jun;26(6):981. doi: 10.1038/s41591-020-0922-4. PMID: 31932797; PMCID: PMC6980793.
[7] Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D, Grutzendler J. TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased Amyloid Compaction and Severe Axonal Dystrophy. Neuron. 2016 Oct 5;92(1):252-264. doi: 10.1016/j.neuron.2016.09.016. PMID: 27710785.
[8] Baligács N, Albertini G, Borrie SC, Serneels L, Pridans C, Balusu S, De Strooper B. Homeostatic microglia initially seed and activated microglia later reshape amyloid plaques in Alzheimer's Disease. Nat Commun. 2024 Dec 5;15(1):10634. doi: 10.1038/s41467-024-54779-w. PMID: 39639016; PMCID: PMC11621353.
[9] Hendrikx T, Porsch F, Kiss MG, Rajcic D, Papac-Miličević N, Hoebinger C, Goederle L, Hladik A, Shaw LE, Horstmann H, Knapp S, Derdak S, Bilban M, Heintz L, Krawczyk M, Paternostro R, Trauner M, Farlik M, Wolf D, Binder CJ. Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. J Hepatol. 2022 Nov;77(5):1373-1385. doi: 10.1016/j.jhep.2022.06.004. Epub 2022 Jun 21. PMID: 35750138.
[10] Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer's disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019 Jul 19;14:5541-5554. doi: 10.2147/IJN.S200490. PMID: 31410002; PMCID: PMC6650620.
[11] Yeh FL, Wang Y, Tom I, Gonzalez LC, Sheng M. TREM2 Binds to Apolipoproteins, Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia. Neuron. 2016 Jul 20;91(2):328-40. doi: 10.1016/j.neuron.2016.06.015. PMID: 27477018.
[12] Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O. The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. Immunity. 2017 Sep 19;47(3):566-581.e9. doi: 10.1016/j.immuni.2017.08.008. PMID: 28930663; PMCID: PMC5719893.
[13] Shi Q, Gutierrez RA, Bhat MA. Microglia, Trem2, and Neurodegeneration. Neuroscientist. 2025 Apr;31(2):159-176. doi: 10.1177/10738584241254118. Epub 2024 May 20. PMID: 38769824; PMCID: PMC11576490.
[14] Bian JH, Yuan CZ, Gu JX, Lin WF, Xiong JQ, Tang ZW, Li A, Shao YF. TREM2 modulates macrophage pyroptosis and inflammatory responses to ameliorate aortic valve calcification. Int Immunopharmacol. 2025 Mar 6;149:114161. doi: 10.1016/j.intimp.2025.114161. Epub 2025 Feb 6. PMID: 39908805.
[15] Johnston KG, Berackey BT, Tran KM, Gelber A, Yu Z, MacGregor GR, Mukamel EA, Tan Z, Green KN, Xu X. Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal and neuronal cells induced by the Trem2R47H Alzheimer's risk gene mutation. Mol Psychiatry. 2025 Feb;30(2):461-477. doi: 10.1038/s41380-024-02651-0. Epub 2024 Aug 5. PMID: 39103533; PMCID: PMC11746152.
[16] Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, Lundgren P, Bleriot C, Liu Z, Deczkowska A, Keren-Shaul H, David E, Zmora N, Eldar SM, Lubezky N, Shibolet O, Hill DA, Lazar MA, Colonna M, Ginhoux F, Shapiro H, Elinav E, Amit I. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. Cell. 2019 Jul 25;178(3):686-698.e14. doi: 10.1016/j.cell.2019.05.054. Epub 2019 Jun 27. PMID: 31257031; PMCID: PMC7068689.
[17] Li RY, Qin Q, Yang HC, Wang YY, Mi YX, Yin YS, Wang M, Yu CJ, Tang Y. TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target. Mol Neurodegener. 2022 Jun 3;17(1):40. doi: 10.1186/s13024-022-00542-y. PMID: 35658903; PMCID: PMC9166437.
[18] Li Y, Xu H, Wang H, Yang K, Luan J, Wang S. TREM2: Potential therapeutic targeting of microglia for Alzheimer's disease. Biomed Pharmacother. 2023 Sep;165:115218. doi: 10.1016/j.biopha.2023.115218. Epub 2023 Jul 28. PMID: 37517293.
[19] Jay TR, von Saucken VE, Landreth GE. TREM2 in Neurodegenerative Diseases. Mol Neurodegener. 2017 Aug 2;12(1):56. doi: 10.1186/s13024-017-0197-5. PMID: 28768545; PMCID: PMC5541421.
[20] Zhao Y, Wu X, Li X, Jiang LL, Gui X, Liu Y, Sun Y, Zhu B, Piña-Crespo JC, Zhang M, Zhang N, Chen X, Bu G, An Z, Huang TY, Xu H. TREM2 Is a Receptor for β-Amyloid that Mediates Microglial Function. Neuron. 2018 Mar 7;97(5):1023-1031.e7. doi: 10.1016/j.neuron.2018.01.031. PMID: 29518356; PMCID: PMC5889092.
[21] Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM, Colonna M. TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med. 2016 May 2;213(5):667-75. doi: 10.1084/jem.20151948. Epub 2016 Apr 18. PMID: 27091843; PMCID: PMC4854736.
[22] Paradowska-Gorycka A, Jurkowska M. Structure, expression pattern and biological activity of the TREM-2/DAP12 molecular complex. Hum Immunol. 2013 Jun;74(6):730-7. doi: 10.1016/j.humimm.2013.02.003. Epub 2013 Feb 28. PMID: 23459077.
[23] Colonna M. The biology of TREM receptors. Nat Rev Immunol. 2023 Sep;23(9):580-594. doi: 10.1038/s41577-023-00837-1. Epub 2023 Feb 7. PMID: 36750615; PMCID: PMC9904274.
[24]Tran KM, Kawauchi S, Kramár EA, Rezaie N, Liang HY, Sakr JS, Gomez-Arboledas A, Arreola MA, Cunha CD, Phan J, Wang S, Collins S, Walker A, Shi KX, Neumann J, Filimban G, Shi Z, Milinkeviciute G, Javonillo DI, Tran K, Gantuz M, Forner S, Swarup V, Tenner AJ, LaFerla FM, Wood MA, Mortazavi A, MacGregor GR, Green KN. A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques. Mol Neurodegener. 2023 Feb 17;18(1):12. doi: 10.1186/s13024-023-00598-4. PMID: 36803190; PMCID: PMC9938579.
[25] Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, Younkin S, Das P, Fryer JD, Bu G. Apolipoprotein E Is a Ligand for Triggering Receptor Expressed on Myeloid Cells 2 (TREM2). J Biol Chem. 2015 Oct 23;290(43):26043-50. doi: 10.1074/jbc.M115.679043. Epub 2015 Sep 15. PMID: 26374899; PMCID: PMC4646257.
[26] Mahley RW. Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism. Arterioscler Thromb Vasc Biol. 2016 Jul;36(7):1305-15. doi: 10.1161/ATVBAHA.116.307023. Epub 2016 May 12. PMID: 27174096; PMCID: PMC4942259.
[27] Oblak AL, Lin PB, Kotredes KP, Pandey RS, Garceau D, Williams HM, Uyar A, O'Rourke R, O'Rourke S, Ingraham C, Bednarczyk D, Belanger M, Cope ZA, Little GJ, Williams SG, Ash C, Bleckert A, Ragan T, Logsdon BA, Mangravite LM, Sukoff Rizzo SJ, Territo PR, Carter GW, Howell GR, Sasner M, Lamb BT. Comprehensive Evaluation of the 5XFAD Mouse Model for Preclinical Testing Applications: A MODEL-AD Study. Front Aging Neurosci. 2021 Jul 23;13:713726. doi: 10.3389/fnagi.2021.713726. PMID: 34366832; PMCID: PMC8346252.
[28] Andrade-Guerrero J, Santiago-Balmaseda A, Jeronimo-Aguilar P, Vargas-Rodríguez I, Cadena-Suárez AR, Sánchez-Garibay C, Pozo-Molina G, Méndez-Catalá CF, Cardenas-Aguayo MD, Diaz-Cintra S, Pacheco-Herrero M, Luna-Muñoz J, Soto-Rojas LO. Alzheimer's Disease: An Updated Overview of Its Genetics. Int J Mol Sci. 2023 Feb 13;24(4):3754. doi: 10.3390/ijms24043754. PMID: 36835161; PMCID: PMC9966419.
[29] Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimers Dement. 2016 Jun;12(6):733-48. doi: 10.1016/j.jalz.2016.01.012. Epub 2016 Mar 24. PMID: 27016693.
[30] Delizannis AT, Nonneman A, Tsering W, De Bondt A, Van den Wyngaert I, Zhang B, Meymand E, Olufemi MF, Koivula P, Maimaiti S, Trojanowski JQ, Lee VM, Brunden KR. Effects of microglial depletion and TREM2 deficiency on Aβ plaque burden and neuritic plaque tau pathology in 5XFAD mice. Acta Neuropathol Commun. 2021 Sep 9;9(1):150. doi: 10.1186/s40478-021-01251-1. PMID: 34503586; PMCID: PMC8428059.
[31] Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, Chen K, Wang N, Zhu L, Can D, Marten Y, Shinohara M, Liu CC, Du D, Sun H, Wen L, Xu H, Bu G, Chen XF. Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer's disease model. Nat Commun. 2019 Mar 25;10(1):1365. doi: 10.1038/s41467-019-09118-9. Erratum in: Nat Commun. 2019 Jul 2;10(1):2923. doi: 10.1038/s41467-019-10950-2. PMID: 30911003; PMCID: PMC6433910.
[32] Dvir-Szternfeld R, Castellani G, Arad M, Cahalon L, Colaiuta SP, Keren-Shaul H, Croese T, Burgaletto C, Baruch K, Ulland T, Colonna M, Weiner A, Amit I, Schwartz M. Alzheimer's disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis. Nat Aging. 2022 Jan;2(1):60-73. doi: 10.1038/s43587-021-00149-w. Epub 2021 Dec 20. PMID: 37118355.
[33] Hong I, Kang T, Yoo Y, Park R, Lee J, Lee S, Kim J, Song B, Kim SY, Moon M, Yun KN, Kim JY, Mook-Jung I, Park YM, Choi S. Quantitative proteomic analysis of the hippocampus in the 5XFAD mouse model at early stages of Alzheimer's disease pathology. J Alzheimers Dis. 2013;36(2):321-34. doi: 10.3233/JAD-130311. PMID: 23603400.
[34] Tran KM, Kawauchi S, Kramár EA, Rezaie N, Liang HY, Sakr JS, Gomez-Arboledas A, Arreola MA, Cunha CD, Phan J, Wang S, Collins S, Walker A, Shi KX, Neumann J, Filimban G, Shi Z, Milinkeviciute G, Javonillo DI, Tran K, Gantuz M, Forner S, Swarup V, Tenner AJ, LaFerla FM, Wood MA, Mortazavi A, MacGregor GR, Green KN. A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques. Mol Neurodegener. 2023 Feb 17;18(1):12. doi: 10.1186/s13024-023-00598-4. PMID: 36803190; PMCID: PMC9938579.
[35] Ennerfelt H, Holliday C, Shapiro DA, Zengeler KE, Bolte AC, Ulland TK, Lukens JR. CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A. 2023 Jun 13;120(24):e2303760120. doi: 10.1073/pnas.2303760120. Epub 2023 Jun 5. PMID: 37276426; PMCID: PMC10268238.
[36] Milazzo R, Montepeloso A, Kumar R, Ferro F, Cavalca E, Rigoni P, Cabras P, Ciervo Y, Das S, Capotondo A, Pellin D, Peviani M, Biffi A. Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model. Nat Commun. 2024 Sep 13;15(1):8024. doi: 10.1038/s41467-024-52301-w. PMID: 39271711; PMCID: PMC11399302.
[37] Vasilopoulou F, Rodríguez-Arévalo S, Bagán A, Escolano C, Griñán-Ferré C, Pallàs M. Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil. Br J Pharmacol. 2021 Aug;178(15):3017-3033. doi: 10.1111/bph.15478. Epub 2021 May 24. PMID: 33817786.
[38] Wu M, Liao M, Huang R, Chen C, Tian T, Wang H, Li J, Li J, Sun Y, Wu C, Li Q, Xiao X. Hippocampal overexpression of TREM2 ameliorates high fat diet induced cognitive impairment and modulates phenotypic polarization of the microglia. Genes Dis. 2020 May 21;9(2):401-414. doi: 10.1016/j.gendis.2020.05.005. PMID: 35224156; PMCID: PMC8843863.
[39] Peng X, Guo H, Zhang X, Yang Z, Ruganzu JB, Yang Z, Wu X, Bi W, Ji S, Yang W. TREM2 Inhibits Tau Hyperphosphorylation and Neuronal Apoptosis via the PI3K/Akt/GSK-3β Signaling Pathway In vivo and In vitro. Mol Neurobiol. 2023 May; 60(5):2470-2485. doi: 10.1007/s12035-023-03217-x. Epub 2023 Jan 20. PMID: 36662361.
[40] Wu Y, Eisel ULM. Microglia-Astrocyte Communication in Alzheimer's Disease. J Alzheimers Dis. 2023;95(3):785-803. doi: 10.3233/JAD-230199. PMID: 37638434; PMCID: PMC10578295.
[41] Vasilopoulou F, Rodríguez-Arévalo S, Bagán A, Escolano C, Griñán-Ferré C, Pallàs M. Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil. Br J Pharmacol. 2021 Aug;178(15):3017-3033. doi: 10.1111/bph.15478. Epub 2021 May 24. PMID: 33817786.
[42] Weller AE, Ferraro TN, Doyle GA, Reiner BC, Crist RC, Berrettini WH. Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology. J Alzheimers Dis. 2022;90(3):1233-1247. doi: 10.3233/JAD-220391. PMID: 36213995.
[43] Gratuze M, Schlachetzki JCM, D'Oliveira Albanus R, Jain N, Novotny B, Brase L, Rodriguez L, Mansel C, Kipnis M, O'Brien S, Pasillas MP, Lee C, Manis M, Colonna M, Harari O, Glass CK, Ulrich JD, Holtzman DM. TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4. Neuron. 2023 Jan 18;111(2):202-219.e7. doi: 10.1016/j.neuron.2022.10.022. Epub 2022 Nov 10. PMID: 36368315; PMCID: PMC9852006.
[44] Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881. doi: 10.1136/jnnp-2018-320106. Epub 2019 Apr 9. PMID: 30967444.
[45] Wang Y, Cao C, Zhu Y, Fan H, Liu Q, Liu Y, Chen K, Wu Y, Liang S, Li M, Li L, Liu X, Zhang Y, Wu C, Lu G, Wu M. TREM2/β-catenin attenuates NLRP3 inflammasome-mediated macrophage pyroptosis to promote bacterial clearance of pyogenic bacteria. Cell Death Dis. 2022 Sep 6;13(9):771. doi: 10.1038/s41419-022-05193-x. PMID: 36068223; PMCID: PMC9448748.
[46]Cosker K, Mallach A, Limaye J, Piers TM, Staddon J, Neame SJ, Hardy J, Pocock JM. Deficits in microglial signaling pathways associated with patient-derived R47H TREM2 variants linked to AD indicate inability to activate inflammasome. Sci Rep. 2021 Jun 25;11(1):13316. doi: 10.1038/s41598-021-91207-1. PMID: 34172778; PMCID: PMC8233372.
[47] Ellwanger DC, Wang S, Brioschi S, Shao Z, Green L, Case R, Yoo D, Weishuhn D, Rathanaswami P, Bradley J, Rao S, Cha D, Luan P, Sambashivan S, Gilfillan S, Hasson SA, Foltz IN, van Lookeren Campagne M, Colonna M. Prior activation state shapes the microglia response to antihuman TREM2 in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2021 Jan 19;118(3):e2017742118. doi: 10.1073/pnas.2017742118. PMID: 33446504; PMCID: PMC7826333.
[48] Tran KM, Kawauchi S, Kramár EA, Rezaie N, Liang HY, Sakr JS, Gomez-Arboledas A, Arreola MA, Cunha CD, Phan J, Wang S, Collins S, Walker A, Shi KX, Neumann J, Filimban G, Shi Z, Milinkeviciute G, Javonillo DI, Tran K, Gantuz M, Forner S, Swarup V, Tenner AJ, LaFerla FM, Wood MA, Mortazavi A, MacGregor GR, Green KN. A Trem2R47H mouse model without cryptic splicing drives age- and disease-dependent tissue damage and synaptic loss in response to plaques. Mol Neurodegener. 2023 Feb 17;18(1):12. doi: 10.1186/s13024-023-00598-4. PMID: 36803190; PMCID: PMC9938579.
[49] Griciuc A, Patel S, Federico AN, Choi SH, Innes BJ, Oram MK, Cereghetti G, McGinty D, Anselmo A, Sadreyev RI, Hickman SE, El Khoury J, Colonna M, Tanzi RE. TREM2 Acts Downstream of CD33 in Modulating Microglial Pathology in Alzheimer's Disease. Neuron. 2019 Sep 4;103(5):820-835.e7. doi: 10.1016/j.neuron.2019.06.010. Epub 2019 Jul 10. PMID: 31301936; PMCID: PMC6728215.
[50] Deczkowska A, Weiner A, Amit I. The Physiology, Pathology, and Potential Therapeutic Applications of the TREM2 Signaling Pathway. Cell. 2020 Jun 11;181(6):1207-1217. doi: 10.1016/j.cell.2020.05.003. PMID: 32531244.
[51] Alrouji M, Yasmin S, Alhumaydhi FA, Sharaf SE, Shahwan M, Shamsi A. Unlocking therapeutic potential: computational insights into TREM2 protein targeting with FDA-approved drugs for neurodegeneration. J Biomol Struct Dyn. 2025 Aug;43(13):6570-6580. doi: 10.1080/07391102.2024.2317987. Epub 2024 Feb 19. PMID: 38373093.
[52] Katzenelenbogen Y, Sheban F, Yalin A, Yofe I, Svetlichnyy D, Jaitin DA, Bornstein C, Moshe A, Keren-Shaul H, Cohen M, Wang SY, Li B, David E, Salame TM, Weiner A, Amit I. Coupled scRNA-Seq and Intracellular Protein Activity Reveal an Immunosuppressive Role of TREM2 in Cancer. Cell. 2020 Aug 20;182(4):872-885.e19. doi: 10.1016/j.cell.2020.06.032. Epub 2020 Aug 11. PMID: 32783915.
[53] Dahlén AD, Roshanbin S, Bucher NM, Sehlin D, Syvänen S. Evaluating the impact of age and treatment on neuroinflammation-related proteins in mouse models of proteinopathies. Exp Neurol. 2025 Sep 22;395:115475. doi: 10.1016/j.expneurol.2025.115475. Epub ahead of print. PMID: 40992617.
[54] Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood-brain barrier. Nat Rev Drug Discov. 2021 May;20(5):362-383. doi: 10.1038/s41573-021-00139-y. Epub 2021 Mar 1. PMID: 33649582.
[55] Wang C, Zong S, Cui X, Wang X, Wu S, Wang L, Liu Y, Lu Z. The effects of microglia-associated neuroinflammation on Alzheimer's disease. Front Immunol. 2023 Feb 22;14:1117172. doi: 10.3389/fimmu.2023.1117172. PMID: 36911732; PMCID: PMC9992739.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Advances in Life Science for Adolescents
This work is licensed under a Creative Commons Attribution 4.0 International License.
